Trial Profile
Safety comformation study of R435 (Bevacizumab) in patients with metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 24 May 2016 New trial record